.RESEARCH STUDY HIGHLIGHT.06 August 2024.
A huge randomized controlled trial with cisgender females highlights the challenges of adherence to a day-to-day oral preexposure treatment routine and illustrates that twice-yearly shot of lenacapavir may maintain efficient HIV prevention levels over 6 months.